Crambescidin Acid from the French Polynesian Monanchora n. sp. Marine Sponge

A. El-Demerdash, S. Petek, C. Debitus, A. Al-Mourabit

► To cite this version:

A. El-Demerdash, S. Petek, C. Debitus, A. Al-Mourabit. Crambescidin Acid from the French Polynesian Monanchora n. sp. Marine Sponge. Chemistry of Natural Compounds, 2020, 56 (6), pp.1180 - 1182. 10.1007/s10600-020-03262-1 . hal-03047904

HAL Id: hal-03047904

<https://hal.science/hal-03047904>

Submitted on 1 Mar 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

CRAMBESCIDIN ACID FROM THE FRENCH POLYNESIAN

Monanchora n. sp. MARINE SPONGE

A. El-Demerdash,^{1,2*} S. Petek,^{3,4} C. Debitus,^{3,4}
and A. Al-Mourabit¹

Marine natural products continue to be rich reservoirs for pharmacological lead compounds [1, 2]. Marine sponges are a distinct multicellular phylum and represent the biggest class of marine invertebrates with approximately 8,900 registered species, though 15,000 species are distributed over seas and oceans [3–5]. *Monanchora* marine sponges are well recognized for producing a high number of structurally divergent bioactive secondary metabolites [6], including acyclic and polycyclic guanidine alkaloids [7–9], steroids [10], terpenoids [11, 12], and long chain fatty acids [13]. These compounds display a myriad of biological potentialities as antimalarial [14], anticancer [15], anti-infective [16], and antiviral [17]. As a part of our ongoing program on bioactive natural products from marine sponges [18–21], we report herein the isolation and identification of five natural products **1–5** for the first time from the *n*-BuOH fraction of *Monanchora* n. sp. sponge.

Chemical investigation of the French Polynesia *Monanchora* sp. marine sponge led to the isolation and identification of one pentacyclic guanidine alkaloid crambescidin acid (**1**) along with four simple nitrogenous compounds, including one nucleoside thymidine (**2**) and three amino acid derivatives, namely phenylethylamine (**3**), tryptophan (**4**), and phenylalanine (**5**).

Compound **1** (11.5 mg) was purified as a viscous pale yellow oily material. It has the molecular formula $C_{22}H_{33}N_3O_4$ as established from its positive HR-ESI-MS m/z 404.2461 $[M + H]^+$ (calcd 404.2549), indicating eight degrees of unsaturation. A preliminary inspection of its 1H NMR recorded in $MeOH-d_4$ showed characteristic signals with similar chemical shifts to those reported previously for crambescidine pentacyclic guanidine alkaloids, confirming the presence of a pentacyclic guanidinic core (vessel), which accounts for five degrees of unsaturation. A detailed analysis of the ^{13}C NMR and HSQC spectra disclosed 22 resonances, which were attributed to two methyls at δ_C 10.9 (C-1) and 22.1 (C-20), two oxymethines at δ_C 72.3 (C-3) and 68.3 (C-19), two azamethines at δ_C 55.6 (C-10) and 54.9 (C-13), two olefinic methines at δ_C 134.5 (C-4) and 131.6 (C-5) within the seven membered ring, giving the sixth degree of unsaturation, one methine at δ_C 54.1 (C-14), and nine methylene groups at δ_C 30.4 (C-2), 24.6 (C-6), 38.4 (7), 38.7 (C-9), 31.0 (C-11), 31.0 (C-12), 33.6 (C-16), 19.7 (C-17), and 32.9 (C-18). Four quaternary resonances, including two sp^3 spiro-carbons at δ_C 85.1 (C-8) and 82.8 (C-15) and two downfield resonances at δ_C 150.8 (C-21) and 181.6 (C-22), are attributed to the guanidinic and free carboxylic acid functionalities, giving the remaining two degrees of unsaturation and satisfying the eight degrees required by HR-MS. The 2D NMR spectral data interpretations, including 1H – 1H COSY, and 1H – ^{13}C HMBC, enabled us to establish and confirm the total structure of **1** and supported its identification as crambescidin acid, a pentacyclic guanidine alkaloid previously isolated from another species, *Monanchora unigiculata* [22]; however, it is recorded here for the first time from *Monanchora* n. sp. Compound **1** displayed promising cytotoxicity against Kb cell lines with inhibitory activities of (100 ± 1) and (80 ± 1) at concentrations of 10 and 1 μM , respectively.

1) Institut de Chimie des Substances Naturelles, CNRS UPR 2301, Univ. Paris-Sud, University of Paris-Saclay, 1, Avenue de la Terrasse, 91198 Gif-sur-Yvette, France, e-mail: eldemerdash555@gmail.com; 2) Organic Chemistry Division, Chemistry Department, Faculty of Science, Mansoura University, 35516, Mansoura, Egypt; 3) Institut de Recherche Pour le Developpement, Unite Mixte de Recherche 241, Ecosystemes Insulaires Oceaniens, BP529, 98713, Papeete, Tahiti, French Polynesia; 4) Institut de Recherche Pour le Developpement, Unite Mixte de Recherche 6539, Laboratoire des Sciences de L'environnement Marin, rue Dumont d'Urville, 29280, Plouzane, France. Published in *Khimiya Prirodnikh Soedinenii*, No. 6, November–December, 2020, pp. 1007–1008. Original article submitted October 21, 2019.

1

The co-isolated simple nitrogenous compounds **2–5** were identified by matching their ^1H NMR and HR-MS spectral data with the literature [23, 24].

General experimental procedures, extraction, isolation, and cytotoxic activity, were performed according to previously published protocol [7].

Animal Material. The sponge was collected off the coast of Hiva Oa ($9^\circ 45.421'\text{S}$ – $139^\circ 08.275'\text{W}$) at 20 m depth using Scuba on 07.09.2009. It was identified as *Monanchora* n. sp. (OTU QM4696) and a reference specimen was deposited at the Queensland Museum (Brisbane, Australia) under accession number QM G331116 [25].

Crambescidin acid (1), pale yellow oil (11.5 mg). HR-ESI-MS m/z 404.2461 $[\text{M} + \text{H}]^+$ (calcd for $\text{C}_{22}\text{H}_{34}\text{N}_3\text{O}_2$, 404.2549). UV (MeOH, λ_{max} , nm) (log ϵ): 276.4 (0.05). IR (neat, ν_{max} , cm^{-1}): 3230, 2967, 2932, 1630, 1542, 1448, 1343, 1114, 1054, 1010, 965, 844, 754. ^1H NMR (500 MHz, CD_3OD , δ , ppm, J/Hz): 5.71 (1H, m, H-5), 5.51 (1H, dd, $J = 11, 2.0$, H-4), 4.35 (1H, m, H-3), 4.23 (1H, m, H-13), 4.03 (1H, m, H-10), 3.82 (1H, m, H-19), 2.69 (1H, d, $J = 5.0$, H-14), 2.59 (1H, dd, $J = 5.0, 4.5$, H-9a), 2.42 (1H, m, H-7a), 2.40 (1H, m, H-6a), 2.32 (4H, m, H-11, 12), 2.13 (1H, m, H-6b), 1.95 (1H, dd, $J = 6.5$, 6.0, H-7b), 1.76 (2H, m, H-17), 1.71 (2H, m, H-16), 1.68 (2H, m, H-18), 1.54 (1H, m, H-2a), 1.46 (1H, m, H-2b), 1.25 (1H, m, H-9b), 1.08 (3H, d, $J = 6.5$, H-20), 0.86 (3H, t, $J = 7.5$, H-1). ^{13}C NMR (125 MHz, CD_3OD , δ , ppm): 181.6 (C-22), 150.8 (C-21), 134.5 (C-4), 131.6 (C-5), 85.1 (C-8), 82.8 (C-15), 72.3 (C-3), 68.3 (C-19), 55.6 (C-10), 54.9 (C-13), 54.1 (C-14), 38.7 (C-9), 38.4 (C-7), 33.6 (C-16), 32.9 (C-18), 31.0 (C-11, 12), 30.4 (C-2), 24.6 (C-6), 22.1 (C-20), 19.7 (C-17), 10.9 (C-1).

ACKNOWLEDGMENT

Financial support from CNRS-ICSN, IRD for the collecting trip aboard R/V Alis, French and French Polynesian Government for the Marquesas Project, as well as ANR (POMARE Project, 2011-EBIM-006-01) are gratefully acknowledged. Amr El-Demerdash's Ph.D. was funded, and completely financed, by a grant from the Egyptian Government (Egyptian cultural Bureau in Paris), which is gratefully acknowledged. We thank F. Pelissier and O. Thoison for HPLC assistance. We give special thanks to J. F. Gallard and K. Hammad for technical assistance and NMR measurements, and to T. Cresteil and G. Aubert for cytotoxicity evaluations.

REFERENCES

1. J. Carlos, *ACS Med. Chem. Lett.*, **9**, 959 (2018).
2. A. R. Carroll, B. R. Copp, R. A. Davis, R. A. Keyzers, and M. R. Prinsep, *Nat. Prod. Rep.*, **36**, 122 (2019).
3. D. Sipkema, M. C. R. Franssen, R. Osinga, R. J. Tramper, and R. H. Wijffels, *Mar. Biotechnol.*, **7**, 142 (2005).
4. M. F. Mehbub, J. Lei, C. Franco, and W. Zhang, *Mar. Drugs*, **12**, 4539 (2014).
5. S. A. M. Khalifa, N. Elias, M. A. Farag, L. Chen, A. Saeed, M. E. F. Hegazy, M. S. Moustafa, A. Abd El-Wahed, S. M. Al-Mousawi, S. G. Musharraf, F. R. Chang, A. Iwasaki, K. Suenaga, M. Alajlani, U. Goransson, and H. R. El-Seedi, *Mar. Drugs*, **17**, 491 (2019).
6. A. El-Demerdash, A. G. Atanasov, A. Bishayee, M. Abdel-Mogib, J. N. A. Hooper, and A. Al-Mourabit, *Nutrients*, **10**, 33 (2018).
7. A. El-Demerdash, C. Moriou, M. T. Martin, A. Rodrigues-Stien, S. Petek, M. Demoy-Schnider, K. Hall, J. N. A. Hooper, C. Debitus, and A. Al-Mourabit, *J. Nat. Prod.*, **79**, 1929 (2016).
8. P. E. Campos, E. F. Queiroz, L. Marcourt, J. L. Wolfender, A. S. Sanchez, B. Illien, A. Al Mourabit, and A. Gauvin-Bialecki, *Planta Med.*, **82**, S1 (2016).

9. A. El-Demerdash, C. Moriou, M. T. Martin, S. Petek, C. Debitus, and A. Al-Mourabit, *Nat. Prod. Res.*, **32**, 1512 (2018).
10. I. I. Kapustina, K. M. Tabakmakher, and T. N. Makar'eva, *Chem. Nat. Compd.*, **47**, 1025 (2012).
11. W. Wang, B. Mun, Y. Lee, M. V. Reddy, Y. Park, J. Lee, H. Kim, D. Hahn, J. Chin, M. Ekins, and S. J. Nam, *J. Nat. Prod.*, **76**, 170 (2013).
12. W. Wang, T. G. Lee, R. S. Patil, B. Mun, I. Yang, H. Kim, D. Hahn, D. H. Won, J. Lee, Y. Lee, and H. Choi, *J. Nat. Prod.*, **78**, 368 (2015).
13. A. El-Demerdash, S. Petek, C. Debitus, and A. Al-Mourabit, *Chem. Nat. Compd.*, **54**, 1143 (2018).
14. P. E. Campos, J. M. Wolfender, E. F. Queiroz, L. Marcourt, A. Al-Mourabit, M. Frederich, A. Bordignon, N. De Voogd, B. Illien, and A. Gauvin-Bialecki, *J. Nat. Prod.*, **80**, 1404 (2017).
15. K. M. Tabakmakher, T. N. Makarieva, L. K. Shubina, V. A. Denisenko, R. S. Popov, A. S. Kuzmich, H. S. Lee, and V. A. Stonik, *Nat. Prod. Commun.*, **11**, 1817 (2016).
16. S. Takishima, A. Ishiyama, M. Iwatsuki, K. Otaguro, H. Yamada, S. Omura, K. Kobayashi, R. W. M. van Soest, and S. Matsunaga, *Org. Lett.*, **11**, 2655 (2009).
17. K. A. El-Sayed, *Stud. Nat. Prod. Chem.*, **24**, 473 (2000).
18. A. El-Demerdash, L. Ermolenko, E. Gros, P. Retailleau, B. N. Thanh, G. B. Anne, and A. Al-Mourabit, *Eur. J. Org. Chem.*, **2020**, 5677 (2020).
19. A. El-Demerdash, C. Moriou, J. Toullec, M. Besson, S. Soulet, N. Schmitt, S. Petek, D. Lecchini, C. Debitus, and A. Al-Mourabit, *Mar. Drugs*, **16**, 146 (2018).
20. A. El-Demerdash, M. A. Tammam, A. G. Atanasov, J. N. A. Hooper, A. Al-Mourabit, and A. Kijjoa, *Mar. Drugs*, **16**, 214 (2018).
21. A. El-Demerdash, A. G. Atanasov, O. K. Horbanczuk, M. A. Tammam, M. Abdel-Mogib, J. N. A. Hooper, N. Sekeroglu, A. Al-Mourabit, and A. Kijjoa, *Mar. Drugs*, **17**, 115 (2019).
22. K. M. Meragelman, T. C. McKee, and J. B. McMahon, *J. Nat. Prod.*, **67**, 1165 (2004).
23. E. Regalado, J. Mendiola, A. Laguna, C. Nogueiras, and O. P. Thomas, *Nat. Prod. Commun.*, **5**, 1187 (2010).
24. Spectral Data for Organic Compounds, http://sdfs.db.aist.go.jp/sdfs/cgi-bin/direct_frame_top.cgi.
25. C. Debitus, BSMPF-1 cruise, Alis R/V, <http://dx.doi.org/10.17600/9100030> (2009).